Docetaxel effectively mobilizes peripheral blood CD34+ cells

Prince, H. Miles; Toner, Guy C.; Seymour, JF; Blakey, David C.; Gates, Priscilla; Eerhard, S; Chapple, J. Paul; Wall, Dominic; Quinn, Michael; Juneja, Surender; Wolf, M.; Januszewicz, E.; Richardson, Gary; Scarlett, J. D.; Briggs, Peter; Brettell, M; Rischin, Danny

doi:10.1038/sj.bmt.1702540

Cited by 15 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CD34 + cell counts were more than 2.00×10 6 /kg at single collection in 27 collections (23.68%). These results are similar to previous reports [20][21][22] . The total number of collected MNC and CD34 + cells had correlated with the WBC count at the bottom after docetaxel treatment (P=0.005, 0.000).…”

Section: Discussionsupporting

confidence: 83%

“…Docetaxel either single or in combination with cyclophosphamide or anthracycline has been reported to successfully mobilize CD34 + cells from peripheral blood [20][21][22] . Prince et al [20] prospectively evaluated docetaxel (100 mg/m 2 ) with G-CSF (10 μg/kg S.C., daily) for mobilization efficiency in 26 patients with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Prince et al [20] prospectively evaluated docetaxel (100 mg/m 2 ) with G-CSF (10 μg/kg S.C., daily) for mobilization efficiency in 26 patients with breast cancer. The median PBSC CD34 + cell content ranged from 1.2 to 5.9×10 6 /kg per day during days 7 to 11 with a median CD34 + content of 3.4×10 6 /kg (range 0.07-15.6) for total 72 PBSC collections.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients

Ren

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor (G-CSF) in breast cancer patients.Methods: A total of 57 breast cancer patients were treated with docetaxel 120 mg/m 2 . When the white blood cell (WBC) count decreased to 1.0×10 9 /L, patients were given G-CSF 5 g/kg daily by subcutaneous injection until the end of apheresis. Peripheral blood mononuclear cells (MNC) were isolated by Cobe Spectra Apheresis System. The percentage of CD34 + cell was assayed by flow cytometry. Results: At a median 6 of days (range 3-8) after the administration of docetaxel, the median WBC count decreased to 1.08×10 9 /L (range 0.20-2.31). The median duration of G-CSF mobilization was 3 days (range 2-7). The MNC collection was conducted 8-12 days (median 10 days) after docetaxel treatment. The median MNC was 5.35×10 8 /kg (range 0.59-14.07), the median CD34 + cell count was 2.43×10 6 /kg (range 0.16-16.69). The CD34 + cell count was higher than 1.00×10 6 /kg in 47 of 57 cases (82.46%) and higher than 2.00×10 6 /kg in 36 cases (63.16%). The CD34 + cell count was higher than 2.00×10 6 /kg in 27 collections (23.68%). The MNC count and the CD34 + cell count were correlated with the bottom of WBC after docetaxel chemotherapy (r=0.364, 0.502, P=0.005, 0.000). The CD34 + cell count was correlated with the MNC count (r=0.597, P=0.000). The mobilization and apheresis were well tolerated in all patients. Mild perioral numbness and numbness of hand or feet were observed in 3 cases. No serious adverse events were reported.Conclusion: Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients

Ren

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…We and others have previously demonstrated the effectiveness of docetaxel with granulocyte colony-stimulating factor (G-CSF) to mobilize PBPCs in patients with breast cancer. 13,14 Consequently, patients received a single cycle of docetaxel (Taxotere, Rhône-Poulenc Rorer Australia, Pty Ltd, Baulkham Hills, NSW, Australia) (100 mg/m 2 ). Dexamethasone (8 mg) was administered over 3 days for a total of six doses commencing the night before chemotherapy and completed the evening of the day after.…”

Section: Mobilization and Collection Of Pbpcsmentioning

confidence: 99%

“…13,15 Apheresis was repeated until sufficient cells to support three separate cycles of HDT had been collected, ie a minimum target of 4.5 ϫ 10 6 /kg (a minimum of 1.5 ϫ 10 6 /kg CD34 + cells for each of the three cycles of highdose therapy) with an optimum target of Ͼ9 ϫ 10 6 /kg. 10 To ensure uniformity, each collection was divided into three separate bags, so that each re-infusion contained PBPCs collected from each day of apheresis.…”

Section: Mobilization and Collection Of Pbpcsmentioning

confidence: 99%

Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

Prince

Rischin

Toner

et al. 2000

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Summary:This phase I study was designed to determine the optimal dosages of a novel repetitive high-dose therapy regimen for patients with metastatic breast cancer (MBC). The planned treatment was three cycles of high-dose cyclophosphamide, thiotepa and docetaxel delivered every 35 days with progressive dose-escalation in successive cohorts. Each cycle was supported by peripheral blood progenitor cells (PBPC) and filgrastim. Eighteen patients were entered into this trial. Of the planned 54 treatment cycles, 44 were delivered and 11 patients completed all three cycles. The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3). There were no treatment-related deaths. Of the 17 patients with evaluable disease, 16 patients responded with six patients achieving a complete remission and an additional four patients achieving no detectable disease (negative restaging including PET scan) but a persistently abnormal bone scan. At a median follow-up of 12 months, median progression-free survival was 11 months with the median overall survival not reached. must still be considered investigational. 6-8 Nonetheless, one approach considered worthy of further investigation is the use of repeated cycles of HDT. 6 We have been interested in developing protocols utilizing repetitive cycles of HDT for patients with MBC, based on administering three cycles of HDT, with each cycle supported by PBPCs.9-11 The primary objective of this study was to develop a suitable regimen that could be delivered largely on an out-patient basis (ie not requiring parenteral nutrition or opiate analgesia for gastrointestinal toxicity) that could subsequently be tested in a randomized trial in patients with MBC.We have previously reported our results of repetitive cycles of HDT using a combination of ifosfamide, thiotepa and paclitaxel (ITP). 9 However, in that study, two patients developed grade 3 renal tubular acidosis (RTA) and we later recognized a further case of RTA in the subsequent phase II study of this regimen.12 Consequently, it was considered that this ifosfamide-related side-effect was unacceptable and in the current study we substituted cyclophosphamide for ifosfamide. Furthermore, as the planned randomized study was to utilize docetaxel in the conventionaldose therapy (CDT) arm, we have substituted docetaxel for paclitaxel in this high-dose therapy regimen. Materials and methods Eligibility criteriaPatients with histologically proven metastatic or locally advanced breast cancer were eligible for entry into this prospective trial. Sufficient PBPCs to support these three cycles of HDT were collected prior to the initiation of HDT (see below). Patients were ineligible if they had a history of prior docetaxel therapy, ventricular arrhythmia, myocardial infarction within 6 months of enrolment, congestive heart failure, hypersensitivity to any of the study drugs, were pregnant or lactating, had an ECOG performance status Ͼ2, life expectancy of less than 2 months, absolute ne...

show abstract

Haemopoietic cytokines

Lewis¹,

Gordon²

2003

The Cytokine Handbook

View full text Add to dashboard Cite

Docetaxel effectively mobilizes peripheral blood CD34+ cells

Cited by 15 publications

References 22 publications

Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients

Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients

Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study

Haemopoietic cytokines

Contact Info

Product

Resources

About